278 related articles for article (PubMed ID: 26403419)
21. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.
Ariffin H; Hainaut P; Puzio-Kuter A; Choong SS; Chan AS; Tolkunov D; Rajagopal G; Kang W; Lim LL; Krishnan S; Chen KS; Achatz MI; Karsa M; Shamsani J; Levine AJ; Chan CS
Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15497-501. PubMed ID: 25313051
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
Stone JG; Eeles RA; Sodha N; Murday V; Sheriden E; Houlston RS
Cancer Lett; 1999 Dec; 147(1-2):181-5. PubMed ID: 10660104
[TBL] [Abstract][Full Text] [Related]
23. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
[TBL] [Abstract][Full Text] [Related]
24. Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma.
McMaster ML; Sun C; Landi MT; Savage SA; Rotunno M; Yang XR; Jones K; Vogt A; Hutchinson A; Zhu B; Wang M; Hicks B; Thirunavukarason A; Stewart DR; Koutros S; Goldstein AM; Chanock SJ; Caporaso NE; Tucker MA; Goldin LR; Liu Y
Br J Haematol; 2018 May; 181(3):372-377. PubMed ID: 29693246
[TBL] [Abstract][Full Text] [Related]
25. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
26. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
27. Identification of a rare polymorphism in the human TP53 promoter.
Attwooll CL; McGown G; Thorncroft M; Stewart FJ; Birch JM; Varley JM
Cancer Genet Cytogenet; 2002 Jun; 135(2):165-72. PubMed ID: 12127401
[TBL] [Abstract][Full Text] [Related]
28. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
[TBL] [Abstract][Full Text] [Related]
29. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
30. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
31. POT1 loss-of-function variants predispose to familial melanoma.
Robles-Espinoza CD; Harland M; Ramsay AJ; Aoude LG; Quesada V; Ding Z; Pooley KA; Pritchard AL; Tiffen JC; Petljak M; Palmer JM; Symmons J; Johansson P; Stark MS; Gartside MG; Snowden H; Montgomery GW; Martin NG; Liu JZ; Choi J; Makowski M; Brown KM; Dunning AM; Keane TM; López-Otín C; Gruis NA; Hayward NK; Bishop DT; Newton-Bishop JA; Adams DJ
Nat Genet; 2014 May; 46(5):478-481. PubMed ID: 24686849
[TBL] [Abstract][Full Text] [Related]
32. Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.
Wong K; Robles-Espinoza CD; Rodriguez D; Rudat SS; Puig S; Potrony M; Wong CC; Hewinson J; Aguilera P; Puig-Butille JA; Bressac-de Paillerets B; Zattara H; van der Weyden L; Fletcher CDM; Brenn T; Arends MJ; Quesada V; Newton-Bishop JA; Lopez-Otin C; Bishop DT; Harms PW; Johnson TM; Durham AB; Lombard DB; Adams DJ
JAMA Dermatol; 2019 May; 155(5):604-609. PubMed ID: 30586141
[TBL] [Abstract][Full Text] [Related]
33. Genetic counseling can influence the course of a suspected familial cancer syndrome patient: from a case of Li-Fraumeni like syndrome with a germline mutation in the TP53 gene.
Hwang SM; Lee ES; Shin SH; Kong SY
Korean J Lab Med; 2008 Dec; 28(6):493-7. PubMed ID: 19127115
[TBL] [Abstract][Full Text] [Related]
34. Population-based analysis of
Simonin-Wilmer I; Ossio R; Leddin EM; Harland M; Pooley KA; Martil de la Garza MG; Obolenski S; Hewinson J; Wong CC; Iyer V; Taylor JC; Newton-Bishop JA; Bishop DT; Cisneros GA; Iles MM; Adams DJ; Robles-Espinoza CD
J Med Genet; 2023 Jul; 60(7):692-696. PubMed ID: 36539277
[TBL] [Abstract][Full Text] [Related]
35. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
[TBL] [Abstract][Full Text] [Related]
36. Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.
Butler KS; Hines WC; Heaphy CM; Griffith JK
Cancer Med; 2012 Oct; 1(2):165-75. PubMed ID: 23342266
[TBL] [Abstract][Full Text] [Related]
37. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
[TBL] [Abstract][Full Text] [Related]
38. A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers.
Wilson TL; Hattangady N; Lerario AM; Williams C; Koeppe E; Quinonez S; Osborne J; Cha KB; Else T
Fam Cancer; 2017 Oct; 16(4):561-566. PubMed ID: 28389767
[TBL] [Abstract][Full Text] [Related]
39. TRF2 promotes dynamic and stepwise looping of POT1 bound telomeric overhang.
Paul T; Liou W; Cai X; Opresko PL; Myong S
Nucleic Acids Res; 2021 Dec; 49(21):12377-12393. PubMed ID: 34850123
[TBL] [Abstract][Full Text] [Related]
40. Fission yeast Pot1-Tpp1 protects telomeres and regulates telomere length.
Miyoshi T; Kanoh J; Saito M; Ishikawa F
Science; 2008 Jun; 320(5881):1341-4. PubMed ID: 18535244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
